Detalhe da pesquisa
1.
Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling.
Breast Cancer Res
; 16(2): R31, 2014 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24678808
2.
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Breast Cancer Res
; 16(1): R7, 2014 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24451109
3.
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Breast Cancer Res
; 15(5): R101, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24168763
4.
Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer.
Cell Cycle
; : 1-20, 2023 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37723865
5.
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Breast Cancer Res Treat
; 135(2): 415-32, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22821401
6.
Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers.
Clin Cancer Res
; 27(2): 585-597, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33097494
7.
Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.
Carcinogenesis
; 31(4): 695-702, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20067990
8.
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
Mol Cancer
; 9: 317, 2010 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21172025
9.
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
Am J Pathol
; 175(5): 1802-9, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19808643
10.
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
J Immunother Cancer
; 7(1): 293, 2019 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31703602
11.
Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Sci Rep
; 8(1): 6829, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29717218
12.
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
JCI Insight
; 3(14)2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046001
13.
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer.
Cancer Res
; 65(1): 246-53, 2005 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15665301
14.
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
Oncotarget
; 8(35): 58847-58864, 2017 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28938602
15.
Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo.
Cancer Prev Res (Phila)
; 10(3): 198-207, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28154203
16.
Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases.
Front Oncol
; 7: 252, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164052
17.
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
Horm Cancer
; 8(5-6): 269-285, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28741260
18.
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
J Clin Oncol
; 23(6): 1152-60, 2005 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15718311
19.
Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
Cancer Res
; 63(10): 2425-33, 2003 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12750262
20.
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Oncotarget
; 7(3): 2921-35, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26621843